Target intelligence / Profile preview

Crystallin gamma E, pseudogene (CRYGEP)

Target
CRYGEP
Molecular classification
Other (specifically, pseudogene; part of the beta-gamma crystallin superfamily—but itself not encoding an active protein)
01

Overview

Crystallin gamma E, pseudogene (CRYGEP), also known as G2, is a member of the gamma-crystallin gene cluster on human chromosome 2 and is classified as a pseudogene. Unlike its functional counterparts (e.g., gamma A–gamma D crystallins), CRYGEP does not code for a full-length, functional protein under normal circumstances. However, mutations affecting regulatory sequences can reactivate its truncated open reading frame, leading to the production of a shortened 6 kDa N-terminal fragment of gamma-crystallin. Reactivation and aberrant expression of this pseudogene have been associated with the genetic eye disorder hereditary Coppock-like cataract, likely due to accumulation of the faulty protein fragment in the lens. CRYGEP is not considered a druggable molecular target nor does it belong to therapeutic target classes such as receptors or enzymes[1][6].

Other names
CRYG5CCLCRYGEP1G2
02

Mechanism of action

None (no mechanism, as it is not a classical drug target)

03

Biological functions

None (as a pseudogene, it does not encode a functional protein; however, overexpression due to genetic reactivation can impact lens physiology)
04

Disease associations

Other (aberrant reactivation in humans has been linked to *hereditary Coppock-like cataract*, likely by expressing a truncated crystallin peptide)
05

Safety considerations

None (no direct therapeutic relevance; however, upregulation may be pathogenic in a genetic context)
06

Interacting drugs

None (no drugs target this non-coding gene)
07

Biomarkers

None (not used as a biomarker for patient selection or monitoring)

Beyond the preview

Go deeper on Crystallin gamma E, pseudogene (CRYGEP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crystallin gamma E, pseudogene (CRYGEP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call